5,517 results on '"VEDOLIZUMAB"'
Search Results
2. Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D (COBRA)
3. A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
4. Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy (SOPRANO-CD)
5. Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
6. A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
7. A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
8. Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
9. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
10. A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
11. Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. (VEDIAN)
12. Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients (VISION)
13. A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
14. A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
15. VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
16. A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
17. Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
18. Vedolizumab for the Treatment of Collagenous Gastritis
19. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
20. Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
21. Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)
22. Defining Predictors of RT Response to Vedolizumab in IBD
23. VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease (VECTORS)
24. VOICE-Early Response to Vedolizumab and Ustekinumab in Participants With Crohn's Disease: A Prospective Observational Study (VOICE)
25. A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (VICTRIVA)
26. Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases.
27. IgA vasculitis preceded by pulmonary hemorrhage in a patient with ulcerative colitis during treatment with vedolizumab.
28. Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab.
29. Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy.
30. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
31. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease.
32. Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.
33. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.
34. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
35. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
36. O USO DO VEDOLIZUMBABE NO TRATAMENTO DA DOENÇA DE CRONH: UMA REVISÃO INTEGRATIVA.
37. Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab.
38. Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review.
39. Mathematical Modeling of Vedolizumab Treatment's Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients.
40. Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo.
41. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications
42. Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab
43. A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
44. PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
45. Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
46. Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success (COMMIT)
47. Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
48. Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
49. EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)
50. Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease (BioIBD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.